TABLE 2.
Outcomes in Patients With Subfoveal Hemorrhage at Last Follow-up Visit
| Patients With Subfoveal Hemorrhage (N = 16) |
|
|---|---|
| Follow-up duration (months), median (range) | 47.6 (6.7–64.5) |
| Baseline VA, n (%) | |
| 20/50 or better | 1 (6.3) |
| 20/63 to 20/160 | 5 (31.3) |
| 20/200 or worse | 10 (62.5) |
| Final VA, n (%) | |
| Better than 20/50 | 6 (37.5) |
| 20/63 to 20/160 | 1 (6.3) |
| Worse than 20/200 | 9 (56.2) |
| Change in VA, n (%) | |
| Gain of ≥6 lines | 3 (18.8) |
| Gain of ≥3 lines | 8 (50.0) |
| Change of >3 lines | 2 (12.5) |
| Loss of ≥3 lines | 6 (37.5) |
| Loss of ≥6 lines | 4 (25.0) |
| Baseline CST (μm), mean ± SEM (range) | 591.7 ± 57.0 (315.0–1231.0) |
| Final CST (μm), mean ± SEM (range) | 285.3 ± 31.9 (158.0–593.0) |
| Time to resolution of SFH in the fovea (months), median (range) | 5.7 (2.8–7.4) |
| Time to complete resolution of SFH (months), median (range) | 7.6 (4.7–13.0) |
| Number of anti-VEGF injections, mean ± SEM (range) | 17.4 ± 3.4 (4.0–48.0) |
| Frequency of anti-VEGF injections, n (%) | |
| Every 4–6 weeks | 5 (31.3) |
| Relatively frequent PRN | 4 (25.0) |
| PRN with long intervals without treatment | 7 (43.8) |
| Final macular status, n (%) | |
| SF fibrosisa | 9 (56.3) |
| Atrophy in area of SF fibrosis, n/n (%) | 5/9 (55.6) |
| SF atrophy | 1 (6.3) |
| Sub-RPE hyperreflective material with atrophy | 1 (6.3) |
| PF fibrosis | 1 (6.3) |
| PF atrophy | 4 (25.0) |
| Location of atrophy, n (%) | |
| No atrophy | 4 (25.0) |
| Within the area of SFH | 9 (56.3) |
| Within and outside the area of SFH | 3 (18.8) |
CST = central subfield thickness; PF = perifoveal; PRN = pro re nata; SF = subfoveal; SFH = subfoveal hemorrhage; VA = visual acuity.
a
One patient had small area of atrophy that was not contiguous with area of SF fibrosis.